Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q99538

UPID:
LGMN_HUMAN

ALTERNATIVE NAMES:
Asparaginyl endopeptidase; Protease, cysteine 1

ALTERNATIVE UPACC:
Q99538; O00123; Q86TV2; Q86TV3; Q9BTY1

BACKGROUND:
Legumain, identified by its unique ability to cleave asparaginyl bonds, is essential for normal lysosomal protein degradation and EGFR degradation. This enzyme, also known as Asparaginyl endopeptidase or Protease, cysteine 1, is required for the normal functioning of renal proximal tubules and plays a significant role in cell proliferation regulation. Furthermore, Legumain's role in MHC class II antigen presentation underscores its importance in immune response.

THERAPEUTIC SIGNIFICANCE:
The exploration of Legumain's functions offers a promising avenue for the development of novel therapeutic approaches. Given its critical roles in protein degradation, cell proliferation, and immune response, targeting Legumain could provide new strategies for treating diseases associated with these biological processes.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.